A study to evaluate the efficacy of theracurmin (highly absorbtive curcumin) for cachexia in treatment-resistant cancer patients

A study to evaluate the efficacy of theracurmin (highly absorbtive curcumin) for cachexia in treatment-resistant cancer patients - A study to evaluate the efficacy of theracurmin for cachexia in treatment-resistant cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014335

Enrollment

Registered

2014-06-22

Start date

2014-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

treatment-resistant cancer patients

Interventions

360mg of theracurmin per day orally for 90 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.pathological confirmed cancer patient 2.treatment-resistant advanced cancer patient 3.Oral intake 4.GPS. 0-2 5.No abnormality in digestive organs due to endogenous diseases

Exclusion criteria

Exclusion criteria: 1.Patients who undergo chemotherapy, operation, or radiation 2.Considered inadequate for the inclusion in the study by the physician

Design outcomes

Primary

Measure	Time frame
immunological effect The expression of cytokines	—

Secondary

Measure	Time frame
At before and 30days,60days, and 90days after the administration of theracurmin 1)Nutrition status 2)QOL score	—

Countries

Japan

Contacts

Public ContactTakashi Iwata

Keio University School of Medicine Department of Obstetrics and Gynecology

iwatatakashi@1995.jukuin.keio.ac.jp0333531211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026